Trial Profile
A Multicenter, Randomized, Double-Blind Factorial Study of the Co-Administration of MK0431 and Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Metformin (Primary) ; Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme Corp.
- 01 Feb 2014 Results published in the Drugs and Aging.
- 12 Jan 2010 Planned patient numbers amended from 1200 to 1208 as reported by ClinicalTrials.gov.
- 01 Mar 2009 Extension study results published in Current Medical Research and Opinion.